• Thermo Fisher outlined a long-term strategy focused on accelerating science, expanding in attractive end markets, driving productivity through its PPI Business System, deploying capital with discipline, and using AI to strengthen execution.
• Scale metrics highlighted included $45 billion of revenue, more than 125,000 colleagues, and $1.4 billion of R&D investment.
• Business mix showed 57% exposure to pharma and biotech end markets, 84% services and consumables, and 51% of revenue in North America.
• Segment revenue was listed as $24.4 billion for Laboratory Products and Biopharma Services, $10.7 billion for Life Sciences Solutions, $7.6 billion for Analytical Instruments, and $4.7 billion for Specialty Diagnostics.
• Historical growth metrics cited a 10% revenue CAGR from 2015 to 2025, a 12% adjusted EPS CAGR, and a 10% free cash flow CAGR.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Thermo Fisher Scientific Inc. published the original content used to generate this news brief on May 20, 2026, and is solely responsible for the information contained therein.